| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Ratings for Ocugen (NASDAQ:OCGN) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 0 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 2 | 0 | 0 | 0 | 0 |
| 3M Ago | 2 | 0 | 0 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $7.0, a high estimate of $7.00, and a low estimate of $7.00. Experiencing a 2.78% decline, the current average is now lower than the previous average price target of $7.20.
The standing of Ocugen among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Daniil Gataulin | Chardan Capital | Maintains | Buy | $7.00 | $7.00 |
| Daniil Gataulin | Chardan Capital | Maintains | Buy | $7.00 | $7.00 |
| Swayampakula Ramakanth | HC Wainwright & Co. | Maintains | Buy | $7.00 | $7.00 |
| Swayampakula Ramakanth | HC Wainwright & Co. | Lowers | Buy | $7.00 | $8.00 |
| Daniil Gataulin | Chardan Capital | Maintains | Buy | $7.00 | $7.00 |
Capture valuable insights into Ocugen's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Ocugen analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Ocugen's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 46.06%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Ocugen's net margin excels beyond industry benchmarks, reaching -1036.46%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Ocugen's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -67.4%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Ocugen's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -20.9%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Ocugen's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.0, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: OCGN
